Nanomedicines towards targeting intracellular <i>Mtb</i> for the treatment of tuberculosis

Donnellan, Samantha ORCID: 0000-0002-3903-5150 and Giardiello, Marco ORCID: 0000-0003-0560-4711 (2019) Nanomedicines towards targeting intracellular <i>Mtb</i> for the treatment of tuberculosis. Journal of Interdisciplinary Nanomedicine, 4 (3). pp. 76-85.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<jats:title>Abstract</jats:title><jats:p>Tuberculosis (TB), caused by <jats:italic>Mycobacterium tuberculosis</jats:italic> (<jats:italic>Mtb</jats:italic>), causes the most human deaths than any other diseases from a single infectious agent. Treatments are long and costly and have many associated side effects. Intracellular bacilli are slow growing and difficult to target, which is augmenting the emergence of multi‐drug resistance. A hallmark trait of TB is the formation of granulomas, chronic cellular aggregates, which limit bacterial growth but provides a survival reservoir where bacilli may disseminate from. Targeting intracellular <jats:italic>Mtb</jats:italic> is challenging, but nanomedicine may offer a solution. Nanomedicine is a significantly growing research area and offers the potential for specific disease targeting, dosage reduction, and intracellular drug delivery. This review discusses the application of the various forms of nanomedicine towards targeting of <jats:italic>Mtb</jats:italic>.</jats:p>

Item Type:	Article
Uncontrolled Keywords:	Bioengineering, Rare Diseases, Tuberculosis, Nanotechnology, Biotechnology, Infectious Diseases, HIV/AIDS, Orphan Drug, 5 Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Infection, 3 Good Health and Well Being
Depositing User:	Symplectic Admin
Date Deposited:	09 Dec 2019 16:20
Last Modified:	15 Mar 2024 05:16
DOI:	10.1002/jin2.61
Open Access URL:	https://doi.org/10.1002/jin2.61
Related URLs:	Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3065620